ICON experts frequently author or contribute to industry trade press. The following are some recent articles.

  • An overview on rare disease research

    ICON's Tim Clark and Will Maier examine the key clinical, regulatory, and commercial challenges associated with the development of therapies for the treatment of rare diseases.

  • A conversation with an expert in drug development

    EBR interviews Colin Orford, Senior Vice President of Drug Development services at ICON, about finding an effective treatment for COVID-19.

  • Use of televisits in studies and related PV concerns

    As a result of the COVID-19 pandemic televisits are becoming strongly considered as an alternative to on- site face-to-face visits, and as a new approach in virtual decentralised trials. ICON’s Xavier Fournie, a member of the EUCROF PharmacoVigilance Working Group, discusses the potential impact of televisits on pharmacovigilance (PV) processes.

  • Encouraging patient participation in real world studies

    Real world data is rapidly becoming the latest frontier for life sciences companies for supporting regulatory filings and conducting drug safety surveillance. ICON experts discuss the critical role of patients and advocacy groups in the June issue of Pharmaceutical Market Europe.

  • Virtual Congresses – Facing up to virtual reality

    The COVID-19 pandemic has challenged the traditional onsite congress engagement experience and forced pharma to rethink face to face events. Read more from Teresa Pena, PhD, Executive Principal Medical Communications in the June issue of Pharmaceutical Market Europe.

  • Running clinical trials for other drugs in the age of COVID-19

    ICON’s CEO Steve Cutler, comments on in-home visits and virtual trials during the COVID-19 pandemic.

  • Going through changes

    ICON's Angela Brown considers what manufacturers can learn from medical device regulation (MDR) and the effect it will have on the in vitro diagnotic landscape (IVD).

  • Challenges and opportunities in harnessing the potential of circulating tumor cells

    Scientific Affairs Manager Candice Willey provides commentary on the difficulties of using CTCs in diagnostic testing despite their promise, the emergence of new CTC technologies to improve tumor sample accessibility, and the benefits of integrating CTC information into clinical trial decisions.

  • The importance of partnering for bioanalytical studies

    BioPharm International speaks with ICON's Robert Kernstock about the need for bioanalytical testing programs and regulatory strategies for potential new biologics.

  • Mitigating the impact of COVID-19 on CV trials and participants

    A thought leadership article authored by Jack Martin, Mary Jane Geiger and Deirdre Albertson which focuses on navigating cardiovascular clinical trials during COVID-19.